Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Brii Biosciences Limited ( (HK:2137) ) just unveiled an announcement.
Brii Biosciences Limited announced the publication of its Phase 2 ENSURE study results in Nature Medicine, highlighting the efficacy and safety of elebsiran combined with pegylated interferon alfa (PEG-IFN α) for chronic hepatitis B treatment. The study demonstrated that the combination therapy resulted in higher hepatitis B surface antigen (HBsAg) loss rates compared to PEG-IFN α monotherapy, particularly among patients responsive to the BRII-179 vaccine. These findings suggest a promising role for BRII-179 in enhancing immune response and expanding treatment eligibility, potentially positioning Brii Biosciences as a leader in hepatitis B curative therapies.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases. The company is engaged in advancing treatments for chronic hepatitis B, utilizing siRNA and therapeutic vaccines to improve patient outcomes.
Average Trading Volume: 6,670,980
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.36B
Learn more about 2137 stock on TipRanks’ Stock Analysis page.